Radiopharm Theranostics Ltd
Business
Radiopharm Theranostics Ltd is a clinical-stage biopharmaceutical company developing radiopharmaceutical platforms for precision oncology, combining diagnostic and therapeutic applications. The company is advancing six licensed platform technologies and a joint venture with M.D. Anderson Cancer Center targeting multiple solid tumors through specialized antibodies, nanobodies, small molecules, and peptides labeled with medical radioisotopes. Clinical programs are in Phase I and II stages across indications including breast cancer, lung cancer, pancreatic cancer, brain metastases, prostate cancer, and glioblastoma, with development initiatives in the United States, Australia, European Union, and other global markets.
Summary from 20-F filed 2025-09-18
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-38.34M |
| Total assets | $86.48M |
| Total liabilities | $43.61M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Radiopharm Theranostics Ltd's CIK number?
Radiopharm Theranostics Ltd's SEC CIK number is 0001949257 (1949257). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Radiopharm Theranostics Ltd's SEC filings?
All of Radiopharm Theranostics Ltd's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.